
Patrizia Giannatempo
@giannatempopatr
ID: 899670545209405440
21-08-2017 16:32:27
1,1K Tweet
474 Followers
699 Following


How to incorporate biomarkers in phase 1? #WorkshopMCCR « you know nothing » in phase 1 without biomarkers with Dr. Tim Yap MD Anderson Cancer Center ESMO - Eur. Oncology EORTC


Vision of the biomarkers in clinical trials with Kurt Schalpe #WorkshopMCCR Yale UniversityMed ESMO - Eur. Oncology EORTC


Day 3 #MCCR25: “The use and risk of AI tools in writing protocols and articles” André Pfob


AI and writing protocols/clinical trials: great talk on tips and tricks with André Pfob Universitätsklinikum Heidelberg #MCCRWorkshop ESMO - Eur. Oncology @eortc


#UroOncoJourney2025 🇮🇹 The multidisciplinary debate on #RCC is always heated 🔥 even more so if the best ( Camillo Porta,Ciro Franzese, Andrea Minervini) take the field, expertly arbitrated by Roberto Iacovelli. However, the goal can only be achieved together!! 🥅 UroFocus ANTURE - Associazione Nazionale Tumore del Rene



Great, unbiased, discussion with Jonathan Rosenberg MD Petros Grivas on ctDNA in #BladderCancer – promising, but not practice-changing yet. – ctDNA is prognostic, not yet predictive – Avoid overinterpreting current data – Use selectively in clinical “gray zones” – Enroll patients in


Kudos to my friend Matteo Santoni who received the prize for the best paper published on European Urology Oncology in 2024 at #UROonco25 in Seville. UroFocus OncoDaily European Urology European Association of Urology (EAU) Francesco Massari Alessandro Volpe Morgan Roupret


Many compliments to our friend Matteo Santoni for this important award. The ARON project goes on!

Congrats Matteo Santoni It was our privilege to highlight this excellent article released in our journal a few months ago European Urology Oncology Riccardo Campi Laura Marandino Ashish M. Kamat, MD, MBBS Elena Castro Ploussard Guillaume Alicia Morgans, MD, MPH Renu Eapen Jeremy Teoh European Association of Urology (EAU)

What a great experience was the last 2 days at the #UROonco25. Great presentations and debates around GU cancers and great honour to be among the speakers for #RCC session. See you in 2026! Thanks to European Association of Urology (EAU) EAU Edu Platform UROONCO Alessandro Volpe 🙏🏻. OncoAlert OncoDaily UroFocus Kidney Cancer



🚨 NEW in #EuropeanUrology By Saum Ghodoussipour Roger Li Sarah P. Psutka MD MS Trinity J. Bivalacqua Joan Palou Redorta et al Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer? This systematic review explores: ✅ BCG-based combos ✅ Gene & immune therapies ✅ Innovative drug


Very excited to share our recent editorial publication reviewing the promise and pitfalls of predictive biomarkers in mUC. Published at JCO Precision Oncology with amazing mentor Shilpa Gupta from Cleveland Clinic. City of Hope Genitourinary Cancer Research Team @CityofHope ascopubs.org/doi/10.1200/PO…


Chech out our study on TMT vs. RC for #MIBC a (long) 🧵(with some stats) sciencedirect.com/science/articl… Critical Reviews in Oncology Hematology (CROH) Daniele Robesti Ploussard Guillaume Giuseppe Fallara University of Cincinnati Cancer Center OncoAlert OncLive SOSS European Association of Urology (EAU) EAU guidelines Amer. Urol. Assn. Society of Urologic Oncology

Le ultime news da Chicago sul #tumoredelrene con i commenti dei nostri esperti Sarah Scagliarini, MD Francesco Massari Sebastiano Buti. Non perdere l'ultima puntata e vai su #Spotify 👉🏻open.spotify.com/episode/0OtCeu… Società Italiana di Urologia SIUrO @uronauti ANTURE - Associazione Nazionale Tumore del Rene Patrizia Giannatempo Luigi Formisano


🌟 #MeetTheEditors Genitourinary Oncology Section of TJ, led by dr. Giuseppe Giuseppe Procopio , dr. Patrizia Patrizia Giannatempo and dr. Marcello Tucci, is focused on evaluation of articles on detection, diagnosis, prevention and treatment of genitourinary tumors, promoting studies


Our last paper in Annals of Oncology: BRCA and HRR muts have similar prevalence in low and high volume mHSPC, but greater impact in low volume😯. Doublets with ARPi or docetaxel result in comparable poor outcomes for BRCA pts annalsofoncology.org/article/S0923-…
